Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545385 · ClinicalTrials.gov registry record · Phase 2
A Study to Test if TEV-48574 is Effective in Relieving Asthma
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT04545385 is a Phase 2 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 65 participants.
The verdict
NCT04545385, a Phase 2 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult participants with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA). The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control. The duration of participant participation in the study is planned to be up to approximately 30 weeks.
Interventions
- DRUG Placebo
- DRUG TEV-48574
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-10-07 |
| Est. Completion | 2022-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04545385
The ClinicalTrials.gov registry entry for NCT04545385 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04545385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04545385 about?
NCT04545385 is a clinical study titled "A Study to Test if TEV-48574 is Effective in Relieving Asthma". The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult participants with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA). The secondary efficacy objec...
What is the current status of trial NCT04545385?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-10-07. Estimated completion is 2022-01-17.
What interventions are being tested in trial NCT04545385?
The interventions under investigation include: Placebo (DRUG), TEV-48574 (DRUG).
Who is sponsoring clinical trial NCT04545385?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.